Basic research in sarcoma models has been fundamental in the discovery of scientific milestones leading to a better understanding of the molecular biology of cancer. Yet, clinical research in sarcoma has lagged behind other cancers because of the multiple clinical and pathological entities that characterize sarcomas and their rarity. Sarcomas encompass a very heterogeneous group of tumors with diverse pathological and clinical overlapping characteristics. Molecular testing has been fundamental in the identification and better definition of more specific entities among this vast array of malignancies. A group of sarcomas are distinguished by specific molecular aberrations such as somatic mutations, intergene deletions, gene amplifications, reciprocal translocations, and complex karyotypes. These and other discoveries have led to a better understanding of the growth signals and the molecular pathways involved in the development of these tumors. These findings are leading to treatment strategies currently under intense investigation. Disruption of the growth signals is being targeted with antagonistic antibodies, tyrosine kinase inhibitors, and inhibitors of several downstream molecules in diverse molecular pathways. Preliminary clinical trials, supported by solid basic research and strong preclinical evidence, promises a new era in the clinical management of these broad spectrum of malignant tumors.

1. Introduction

Remarkable gains in the understanding of cancer biology have been attained in the past two decades. Novel methodologies and laboratory techniques have allowed molecular dissection of cancer cells leading to a more precise portrait of tumorigenesis. The biological and molecular characteristics of transformed cells that produce and sustain malignant growth have been organized in a coherent and comprehensive manner by Hanahan and Weinberg [1]. Sustained growth, evasion of growth suppressors, resistance to death, induction of angiogenesis, and the ability to invade and spread are fundamental tumor characteristics, all of which have underlying molecular correlates that scientists are beginning to unravel and understand. More recently, other enabling characteristics have supplemented these initial concepts, namely, avoidance of immune destruction, tumor-promoting inflammation, deregulation of cellular energy pathways, and genomic instability [1].

Although these principles are applicable to all malignancies, individual classes of tumors and even individual patients differ in the particular specificities of the complex process of malignant growth. Further, this is a multistep dynamic process subject to change and adaptation over the course of the disease, from premalignant lesions to metastatic spread.

Sarcoma research has lagged behind other cancers because of the rarity of these tumors and the multiple clinical and pathological entities that compose these malignancies. Yet, research work with sarcomas has been central in elucidating many of the modern concepts of cancer biology including the molecular signals driving tumor growth and permanence. Even though few advances in the treatment of
these highly resistant tumors have occurred, some milestones have been carved based on clinical and bench research in sarcoma. This paper highlights some of the most outstanding work in the past, current knowledge of the molecular biology of sarcomas and the challenges to control or cure these rare, heterogeneous malignancies.

1.1. The Rous Sarcoma Virus. The seminal paper by Rous describing the ability to transfer an avian spindle cell sarcoma from one Plymouth Rock hen to another was largely dismissed as irrelevant to human disease [2]. Rous described experiments that eventually led to our modern understanding of the genesis of cancer. Later, Rous published work describing the transmission of sarcoma using tumor cell-free extracts indicating that a biological agent on the filtrate could cause tumor growth and could be propagated through subsequent passages. These observations opened the field of tumor virology and would link sarcoma research intimately to the field of cancer research.

The agent responsible for this unprecedented discovery was a retrovirus (Rous sarcoma virus (RSV)). A cadre of researchers began to unravel the mystery of this finding over the years. Remarkably, it took more than 50 years from the initial report for the world to realize the magnitude of the discovery when the existence of a genetic sequence in the RVS capable of inducing transformation, the src gene was discovered. The src-encoded tyrosine kinase (TK) was the first evidence of TK activity involved in malignant transformation [3], and it was the first to demonstrate that activation occurs by phosphorylation of the aminoacid tyrosine in host cell proteins. These enzymes have been shown to be essential for the malignant transformation of cells by oncogenic signals [4]. Steadily the functional relationship between oncogenic protein activity and receptor signaling began to emerge into a cohesive model that occupies much of the current research in carcinogenesis and biology of cancer cells. The eventual development of targeted therapies, interfering with these molecular pathways saw the dawn of a modern approach to cancer therapy.

The viral etiology of cancer in vertebrates evolved from these observations [5]. Viral particles were described in multiple vertebrate species and culminated with the identification of the first retroviral oncogene named “v-src” and its cellular homologue (c-src). It was realized that the viral oncogenes derived from functional cellular genes (proto-oncogenes) capable of inducing malignant transformation upon activation [6]. Subsequent years saw the identification of a number oncogenes and tumor-suppressor genes that were altered in human cancer. The concept of clonal evolution and a molecular model of multistep tumorigenesis evolved from these discoveries [7].

1.2. RAS and Human Oncogenes. As the concept that cancer was a disease of altered genes gained momentum, research with other animal sarcoma-inducing viruses led to further remarkable discoveries. The viruses that stand out were the rat sarcoma virus from the 1960s. The ras genes from the Kirsten sarcoma virus (KRAS), the Harvey sarcoma virus (HRAS), and later NRAS were shown to encode highly related proteins (H-Ras, N-Ras, K-Ras4A, and K-Ras4B) [8]. Later on, the cellular homologues of KRAS was found in human cancer cells (1982). A single aminoacid mutation was proven to allow the constitutive activation of the oncogene. Thus, the concept of cellular oncogenes capable of inducing human cancer was confirmed by the cloning of c-RAS the first human oncogene. The Ras proteins were later found to be GTPases involved in cellular signal transduction for cell growth and division. Activating mutations in Ras have been described in 20–25% of all human tumors and much higher in some specific tumor types [9]. During the 1990s the role of KRAS in tumorigenesis was established and the molecular signaling pathways involved in this process began to be unraveled [10].

Enormous scientific gains in the understanding of human cancer derived from the study of these viral agents. These discoveries, derived from the study of sarcomas, will remain engrained in the annals of history of cancer.

1.3. Coley’s Vaccine. The first systematic study of immunotherapy for the treatment of malignant tumors began in 1891 by William Coley. Following the clinical observation of a dramatic response of one young patient to an injection of streptococcal organisms Coley treated, amidst much criticism and controversy, hundreds of patients with soft-tissue and bone sarcomas over a span of four decades [11]. Later he would use heat-killed streptococcal organism and Bacillus prodigiosus (Serratia marcescens), a concoction that became known as Coley’s Toxin. By 1920 his work would become of ill repute. The Bone Sarcoma Registry (the first established cancer registry) declared lack of sufficient evidence of the therapeutic benefit claimed by Coley. Regardless of the longlasting debate surrounding his work, Coley’s research would set the foundations on cancer immunotherapy. The scientific interest on this approach will rapidly grow as the biology of the immune system was progressively better understood. We could now assume that the effects of the Coley’s toxins were mediated by activation of the immune system, with ensuing cellular activation and production of powerful cytokines (e.g., interleukins, interferons, tumor necrosis factor, etc.), some of which would become therapeutic tools in contemporary cancer immunotherapy.

1.4. Sarcomas and Interferon. The discovery of interferon was dismissed as a laboratory curiosity until Gresser showed that human leukocytes produced substantial amounts of these cytokines and later described an antiproliferative effect on cultured cells and animals [12]. Immunomodulating properties were also ascribed to interferon (IFN) and triggered enormous interest to investigate IFN as a potential anticancer agent, amidst the growing evidence of the existence of cancer-inducing transforming viruses. Strander pioneered the initial clinical use of IFN in human cancer. His group showed in vitro evidence of the activity of IFN in osteosarcoma (OS) cells and in human sarcoma tumors transplanted into mice which led to studies using IFN treatment in OS after surgery [13]. At a decade of followup,
Table 1: HHV-8 Genes and role in Kaposi Sarcoma.

| Latent genes | Effects | Other properties |
|--------------|---------|------------------|
| V-cyclin (ORF 72) | Constitutively activates CDK6 | Phosphorylates pRb; Releases E2F |
|              | Interferes with cyclin-dependent cell cycle arrest | Activates S-phase genes |
|              | Bypasses inhibitory controllers of cell cycle regulation (p16, p21, and p27) | |
| v-FLIP (ORF 71) | Competes with proapoptotic signals mediated via FAS-FADD | Oncogenic |
| LANA (ORF 73) | Competes with E2F transcription factor for binding to pRb | Controls genes triggering the switch to lytic phase |
| Kaposin (K12) | Blocks tumor suppressor genes p53 | Oncogenic |
| K10.1 (LANA-2) | Blocks IFN- and IRF-mediated transcriptional activation; binds p53? | |

| Lytic genes | Effects | Other properties |
|-------------|---------|------------------|
| vIL-6 (ORF K2) | Activates gp130 independently of IL-6R | Autocrine and paracrine loops |
|             | Activates NFXB; constitutively activates GPCR. | Oncogenic |
|             | Activates JAK1 and STAT 1/3 pathways | |
| vGPCR (ORF 74) | Induces transcription of VEGF and MMP-9 | Oncogenic |
| vMIP-I and vMIP-II (ORF K4) | Constitutively activate GPCRs; binds IL-8 | Angiogenic |
|             | CCR-3 and 4 agonist | Entry coreceptor for HIV-1 |
|             | Broad spectrum cytokine receptor antagonist. | |
| vBcl2 (ORF 16) | Antiapoptotic activity | Oncogenic |
|              | Inhibits bax | |

sarcoma-specific survival was 38% for the patients treated before 1985 and 63% for the group treated with higher total IFN dose afterwards. Because of the uncontrolled study design, there is no way to confirm a direct clinical benefit from IFN therapy in this pioneering study. Yet, continuous interest remains in exploring the potential benefit of IFN in OS, and a prospective randomized trial was launched by the European and American Osteosarcoma Study Group (EURAMOS 1) using pegylated IFN. We now know that IFN is an endogenous antiangiogenic regulator. IFN-α mediates cellular signaling via the JAK/STAT cascade with complex interaction with other signaling pathways including MAPK, PI3K, mTOR, and IFN-induced apoptosis via activation of Bak and Bax and the mitochondrial pathway. All of these molecular cascades are seemingly necessary in generating an IFN response [14, 15].

1.5. Kaposi’s Sarcoma: A Model of Viral Carcinogenesis. Kaposi’s sarcoma (KS) was originally described in 1872 and for decades remained as an uncommon low-grade, slow-growing tumor affecting predominantly patients of Jewish and Mediterranean origin (“Classic” KS). In the 1950s, an endemic type of KS was identified in equatorial Africa regions with some patients exhibiting rapid and aggressive course and high mortality. Epidemiological data from this endemic form raised suspicion of a viral etiology in association with increased relevance of oncogenic viruses in other malignancies [16].

Renewed efforts to identify the cause of KS came as a result of the high incidence of KS in patients with AIDS. Epidemiological data led to the proposal that a sexually transmitted agent was responsible for KS [17]. Distinct DNA fragments of a herpes virus from KS were first isolated in 1994 [18]. The new virus was found to be a gamma herpes virus and was designated HHV-8. HHV-8 DNA is found in over 90% of specimens from classic KS, endemic KS, posttransplant KS, and epidemic KS.

Expression of multiple cellular-derived oncogenes has been identified by genetic dissection of the HHV-8 during its latent and lytic phases [19, 20]. KS lesions contain predominantly HHV-8 in latent phase. In these cells, HHV-8 expresses a limited number of “latent” genes (Table 1). The gene expression during the lytic phase is initiated by the HHV-8 replication transactivation activator gene (ORF 50; RTA), which is under regulatory control by LANA-1. RTA activates DNA and protein synthesis resulting in replication and assembly of new infective viral particles [19]. Lastly, the role of HIV virus in AIDS-related KS has been studied and suggests a synergistic effect with HHV-8 in the genesis of the tumor in these patients. The HIV Tat protein has been shown to compete with heparin sulfate proteoglycans, which bind β-fibroblast growth factor (β-FGF), increasing free levels of this angiogenic factor. KS has been described as an angiogenic neoplasm, and the genetic profile of the spindle cells, a major cellular component of KS lesions, closely resembles lymphatic endothelium [21]. These
endothelial cells are responsive to angiogenic growth factors. Second, HIV Tat activates HHV-8 increasing expression of several early viral genes (Table 2).

IFN was shown to produce antitumor effects in AIDS patients with KS [22, 23] leading to the FDA approval of IFN for treatment of AIDS-associated KS in 1988. However, it was the control of HIV replication with highly antiviral antiretroviral therapies (HAART) combinations that resulted in a significant decline in the incidence of KS in AIDS patients. Whether this was the result of suppression of HIV-Tat (or other HIV genes) or the partially restoration of immunity, this epidemiological shift reinforces the participatory role of HIV in the tumorigenesis of KS.

KS stands out as one bona fide example of viral carcinogenesis in man. Although many factors are required for the malignant transformation to occur, HHV-8 is the primary trigger of a cascade of molecular events that lead to the development of this unique type of sarcoma.

1.6. Gastrointestinal Stromal Tumors (GISTs). The term “gastrointestinal stromal tumors” (GIST) refers to mesenchymal tumors of the gastrointestinal tract with features of neurogenic or myogenic differentiation but neither of neurogenic (S100-protein negative) or of smooth muscle origin (absence of myofilaments). Somatic mutations of c-KIT are involved in the genesis of these tumors. The transforming viral gene, Hardy-Zuckerman 4 feline sarcoma virus (v-KIT; HZ4-FeSV), was discovered in 1983 in feline sarcomas [24]. The c-KIT gene is the cellular homologue of a v-KIT that encodes a TK growth factor receptor (CD 117) and has been associated with growth and differentiation of immature cells [25]. The CD117 receptor is expressed by the interstitial cells of Cajal (ICC) and by neoplastic cells most notably by GIST [26]. From these observations, it was concluded that the ICC was most likely the cell of origin of GIST. The binding of the ligand Steel factor (SLF), or stem-cell factor to CD117 results in activation of KIT TK and constitutive activation of its signal transduction. Mutations of c-KIT resulted in gain of function of the KIT TK and constitutive activation of its molecular downstream pathways, predominantly the PI3K pathway [27, 28].

Approximately 75–85% of GIST patients express activating mutations of KIT of which exon 11 is the most common (57–70%), followed by exon 9 (5–18%) and rarely exon 13 and 17 domains (<2%). Only 5% of patients exhibit mutations in PDGFR and some patients exhibit neither KIT nor PDGFR (10–15%) [29]. Work with a c-KIT expressing human myeloid leukemia cell line proved that STI 571 (imatinib mesylate) was able to block c-KIT autophosphorylation [30]. Shortly after, a human GIST cell line expressing an active KIT mutation was completely inhibited by imatinib [31]. These findings translated into the first report on the clinical efficacy of imatinib in a single patient with GIST [32] which was followed by an auspicious phase II trial [33] and a fast track FDA approval. Thus, GIST became the first solid tumor, where therapeutic interference of a mutated TK mutation showed clear benefit.

Later work demonstrated that the specific location and nature of the activating mutation on KIT influences the clinical behavior of GIST. Most nonresponsive patients and almost all patients with early relapses were shown to carry an exon 9 KIT, PDGFR mutations or a wild type. Although KIT exon 11 missense mutations are found predominantly in lower-grade, favorable-outcome, GIST mutations involving deletion or duplication of multiple amino acids in exon 11 have been related to poorer outcome [34]. Imatinib resistance has been related to survival pathways that circumvent KIT blockade linked to secondary mutations in KIT exons 13, 14, 17, or 18 which typically develop in tumors with primary exon 11 mutations leading to late progression in 50 to 70% of the patients [35].

Sunitinib, a multifunctional TK inhibitor, produces responses in patients with relapsing or resistant to imatinib [29]. In vitro inhibition of PI3K pathway in imatinib resistant cells arrests cell growth and induces apoptosis [35], suggesting that this may be a mechanism of action of sunitinib in imatinib-resistant patients. These observations are important as they relate to the fact that even specific targeted molecular therapies are not infallible or permanent and extensive further work lies ahead.

### Table 2: HIV and Kaposi Sarcoma. HHV-8 genes activated by HIV-Tat.

| HHV-8 genes | Effects | Other properties |
|-------------|---------|-----------------|
| vGPCR (ORF 74) | Constitutively activates GPCR | Oncogenic |
| Antia apoptotic activity | Promotes synthesis of VEGF | Angiogenic |
| Antiapoptotic activity | Inhibits bax | Oncogenic |
| Interferon regulatory factor homolog | Activates the c-myc oncogene | IFN-mediated antiviral immunity |

2. Molecular Biology of Sarcomas

The molecular findings in KS and GIST paved the way to an intensive search for molecular targets with a clinical translational potential. Bone and soft-tissue sarcomas encompass a very heterogeneous group of tumors with diverse pathological and clinical overlapping characteristics. Histomorphology distinguishes pleomorphic and nonpleomorphic tumors and spindle cell, epitheloid and small blue round cell tumors. With immunohistochemistry some tumors can be identified with epithelial or mesothelial line of differentiation. The advent of molecular testing has further assisted in the identification of more specific entities among this vast array of malignancies.

At a molecular level, a group of sarcomas are distinguished by specific molecular aberrations including somatic mutations, intergene deletions, gene amplifications, and reciprocal translocations. Others carry complex karyotypes
Table 3: Reciprocal translocations in sarcomas.

| Tumor | EWS translocations | Fused genes | Incidence (%) |
|-------|--------------------|-------------|---------------|
| Ewing sarcoma/PNET | t(11;22)(q24;q12) | EWS-Fli1 | 85 |
| | t(21;22)(q22;q12) | EWS-ERG | 10 |
| Desmoplastic small round cell tumors | t(11;22)(q13;q12) | EWS-WT1 | 75 |
| Myxoid liposarcoma | t(12;22)(q13;q12) | EWS-CHOP | 5 |
| Clear cell sarcoma | t(12;22)(q13;q12) | EWS-ATF1 | >90 |
| Myxoid liposarcoma | t(12;16)(q13;q11) | FUS-CHOP | 95 |
| Extraskeletal myxoid chondrosarcoma | t(9;22)(q22;q11) | EWS-CHN | 75 |
| | t(9;17)(q22;q11) | RBPS6-CHN | 20 |

| Tumor | Non-EWS Translocations | Fused genes | Incidence (%) |
|-------|------------------------|-------------|---------------|
| Synovial sarcoma | t(X;22)(p11.23;q11) | SYT-SSX1 | 65 |
| | t(X;18)(p11.21;q11) | SYT-SSX2 | 35 |
| Alveolar Rhabdomyosarcoma | t(2;23)(q35;q14) | PAX3-FKHR | 75 |
| | t(1;13)(q36;q14) | PAX7-FKHR | 10 |
| Congenital fibrosarcoma | t(12;15)(q13;q25) | ETV6-NRTK3 | Unknown |
| Alveolar soft part sarcoma | t(X;17)(p11;q25) | ASPSCR1-TFE3 | 99 |

and nonspecific genetic alterations. The majority of high-grade sarcomas with complex karyotypes have a high frequency of protein p53 (p53) and retinoblastoma protein (pRb) mutations as well as impairments in DNA repair and severe chromosomal instability, but no specific genetic alterations [36–40].

These molecular aberrations have undoubtedly improved the diagnostic capabilities to confirm the nature of many STS. However, the predictive and prognostic significance of these anomalies is hampered by the lack of standardization of methodologies and the small sampling amongst many of the several subtypes of sarcomas. Early reports that associate molecular abnormalities in ES and SS with prediction of outcome have been disputed in larger studies [41, 42].

2.1. Somatic Mutations. The gain-of-function KIT and PDGFR gene mutations in GIST are the most notable examples of this type of genetic abnormality in soft-tissue sarcomas.

2.2. Intergene Deletions. Rhabdoid tumors, which are highly aggressive and carry a poor prognosis, show partial or complete loss of the hSNF5/INI1 gene (chromosome 22q11.2). This gene is a core member of the SWI/SNF chromatin remodeling complex, and its loss leads to cell cycle progression. This abnormality is also present in 50% of malignant peripheral nerve sheath tumors and epithelioid sarcomas [37].

2.3. Amplifications. Amplifications of genomic regions are not specific for a given sarcoma subtype, but amplification of the murine double minute gene (MDM2) and the cyclin-dependent kinase 4 (CDK4) at chromosome 12q13–15 are highly characteristic in dedifferentiated liposarcomas (LPS) [40].

2.4. Reciprocal Translocations. Numerous translocations have been described in the past two decades that define 15–20% of sarcomas (Table 3). The first translocation identified in patients with Ewing sarcoma (ES) between the EWSR1 gene on chromosome 22q12 and FLI1 (Friend leukemia virus integration 1), a member of the ETS gene family of transcription factors on chromosome 11q24, was reported in 1992 [41]. This remains the most frequent abnormality, present in 85% of the patients. Other less frequent translocations have been described with other members of the ETS gene family. These translocations defined the ES family of tumors including the peripheral primitive neuroectodermal tumors (PNET) and became a critical diagnostic tool and a window to the pathogenesis of these and other sarcomas. The translocated genes give origin to a chimeric fusion gene encoding an aberrant transcription factor which alters several cell signaling pathways affecting proliferation and apoptosis leading to invasiveness and metastasis [43].

Several fusion proteins have been described resulting from translocations that involve the EWS family of genes and the ETS family in various types of sarcomas. ES includes fusion genes between EWS and FLI1 (85%) and ERG (10%) and rare cases involving ETV1, ETV4, FEV, and other ETS genes. Other gene products with a high homology to EWS can replace EWS in different fusions including CHN (or NOR1) in extraskeletal myxoid chondrosarcomas and CHOP (or CEBPE) in a proportion of myxoid LPS [38–40].

A second group of fusion genes are formed by non-EWS translocations and have been described in various types of sarcomas notably synovial sarcoma (SS), alveolar, rhabdomyosarcoma (ARMS), and myxoid LPS (Table 3).
These translocations have a tight specificity for a particular cell type. Gene fusions seem to only occur in susceptible cells at a given stage of development. Those cells surviving the abnormal translocation will eventually suffer malignant transformation. Accordingly, these fusion genes and their transcriptional targets may define the tissue lineage where the tumor originates, the phenotype of the transformed cells, and perhaps the clinical course of each subtype of sarcoma. ES is a striking example of lineage specificity [44].

The fusion genes are believed to promote carcinogenesis via stimulation or suppression of other genes involved in cell proliferation (i.e., upregulation of PDGF-C, CCDN1, and c-MYC), evasion of growth inhibition (via downregulation of CDK inhibitors and TGF-β receptor), escape from senescence by upregulation of hTERT, escape from apoptosis by repression of IGFBP-3 promoter, induction of angiogenesis by increasing VEGF and promoting invasion and metastases via matrix metalloproteinases (MMPs). Some fusion genes perform as autocrine stimulation loops. In dermatofibrosarcoma protubersans (DFSP), the growth factor platelet-derived growth factor B (PDGFB) is constitutively activated by the collagen, type I, alpha 1 (COL1A1) promoter in chromosome 17. In congenital fibrosarcoma the ETV6-NTRK3 fusion product (t(12; 15)(p13; q25)) results in constitutive activation of Ras/MAPK mitogenic pathway and PI3K highly activated in chromosome 17 and the TFE3 locus on the X chromosome (der(17)t(X; 17)(p11q25)) [48]. MITF, TFE3, TFEB, and TFEC comprise a family of transcription factors that share a highly homologous DNA binding and dimerization domain. These proteins bind identical DNA elements, suggesting that they may activate common downstream targets [49].

2.5. The Insulin-Like Growth Factor System (IGF). The role of this pathway has been recognized as one of the major signaling pathways in the tumorigenesis of several sarcomas. The IGF consists of 3 main ligands: IGF-I, IGF-II, and insulin which bind to four types of membrane receptors, namely, IGF-1R, igf-2R, the insulin receptor (1R), and hybrid receptors. IGF-1R and Insulin receptors are 84% homologous and interact with each other to form heterodimers with high affinity to their ligands. In addition, there are IGF circulating binding proteins (IGFBP) that modulate the availability of the free ligands to the receptors. The concentration of the ligands and the binding proteins are under the influence of growth hormone and liver synthesis. The binding of ligand and receptor activates intracellular signaling cascades via the PI3K and MAPK pathways. Abnormalities among or along these numerous molecules have been described in different human malignancies and particularly in sarcomas [50, 51].

Several sarcoma fusion genes and other molecular anomalies have been shown to upregulate ligand (IGF-1 or IGF-2) or receptor (IGF-1R) expression and, in ES, to downregulation of IGFBP-3 (Table 4). The IGF system, particularly the IGF-1R, has been validated both in vitro and in experimental animal models as a central participant in the induction of malignant transformation in ES, RMS, leiomyosarcoma (LMS), and other sarcomas. Furthermore, preliminary clinical observations have related markers of the IGF system to tumor behavior and prognosis [51].

2.6. The PI3K Pathway. Heightened expression of IGF-1R has been related to loss of transcriptional repressors (p53) or increase in transcriptional activators in various human cancers. Upregulation of IGF-1R results in sustained activation of downstream PI3K and MAPK pathways (Figure 1). The carcinogenic potential of abnormal or unregulated PI3K/AKT or RAS/MAPK pathways' signaling is related to their regulatory role in cell cycle progression, cell growth

### Table 4: The IGF System in sarcoma pathogenesis.

| Tumor                        | Abnormal genes | Involved ligand | Involved receptor | Other properties                  |
|------------------------------|----------------|-----------------|------------------|-----------------------------------|
| Ewing sarcoma/PNET           | EWS-FLI1       | IGF-1           | IGF-1R           | Downregulates IGFBP-3             |
| Synovial sarcoma             | SYT-SSX1/SYT-SSX2 | IGF-2           | IGF-1R           |                                   |
| Alveolar rhabdomyosarcoma     | PAX3-FKHR/PAX7-FKHR | IGF-2           | IGF-1R           | Autocrine loop                    |
| Desmoplastic small round cell tumors | EWS-WT1       | ?               | IGF-1R           |                                   |
| Congenital fibrosarcoma       | ETV6-NTRK3     | IGF-2           | IGF-1R           |                                   |
| Embryonal rhabdomyosarcoma    | LOH 11p15.5 pften | IGF-2           | IGF-1R           | Autocrine loop                    |
| Leiomyosarcoma                | Complex karyotypes | IGF-2           | IGF-1R           | PI3K highly activated             |
| Osteosarcoma                  | Complex karyotypes | IGF-1, IGF-2   | IGF-1R           |                                   |
| Kaposi sarcoma                | Complex karyotypes | ?               | IGF-1R, IR-A     |                                   |
| GIST                         | Lacking KIT, PDHFR mutations | IGF-1, IGF-2 | IGF-1R           | Poorer Prognosis                 |
and proliferation, differentiation, and apoptosis [50, 51]. Activation of PI3K turns on AKT, key molecular “node” acting as a master switch, which triggers multiple downstream signaling pathways (including mTOR activation) promoting proliferation and increased cell survival, antiapoptotic signals and upregulation of cell-cycle proteins (cyclin D1 and CDK4). Recent experimental evidence supports the central role of AKT in STS with complex karyotypes. In a mouse model using and an adenovirus with Cre-recombinase and conditional mutations of Kras and p53 over 90% of the animals developed high grade sarcomas, resembling malignant fibrous histiocytoma (MFH) [52]. Another model using mice genetically inactivated for pTEN (phosphatase and tensin homolog) over 80% of the animals developed abdominal LMS [53].

2.7. MAPK. Overexpression and activation of the MAPK pathway (M KK) has been demonstrated in several epithelial malignancies and related to tumor proliferation and metastases. This pathway is coactivated by IRS system with PI3K but its role in the genesis of sarcoma is less defined. Growth factor-induced activation of Ras leads to the activation of Raf, followed by the activation of MAPK/ERK kinases (MEK1-MEK2) and lastly the activation of ERK1 and ERK2 (Figure 1). The latter proteins regulate cell proliferation, survival, differentiation, and migration. In one study, RAF1 and MEK 1/2 mRNA were detected in STS cell lines and OS specimens and demonstrated dose- and time-dependent inhibition of cell growth when treated with a MEK inhibitor [54]. Similar observations have been reported in SS where TK inhibition with sorafenib inhibited the MKK pathway,
downregulated cyclin D1 and pRb levels, caused G1 arrest, and induced apoptosis [55]. In a xenograft model, MKK signaling was necessary for tumor growth and vascularization and treatment with anthrax lethal toxin (LeTx) produced extensive tumor death and antiangiogenic effects. LeTx contains lethal factor (LF), a zinc metalloprotease that cleaves and inactivates several MKK proteins, suggesting that MKK had a predominantly proangiogenic effect in this model [56].

2.8. The Role of mTOR Pathway. Activation of PI3K-AKT is a convergence point of activation of growth factor receptors driving the growth of various sarcomas (Figure 1). Intrinsic activation of the mTOR pathway in sarcomas is the result of abnormal signaling of these pathways [57]. Other mechanisms explaining over activation of mTOR involve the loss of regulatory inhibitory gene activity of the tuberous sclerosis complex (TSC) proteins or PTEN inactivation by methylation of the promoter, gene mutation, or allelic deletions such as those reported in perivascular epithelioid cell tumors (PEComas). Loss of LKB1 protein also leads to activation of the mTOR signaling in a manner similar to the loss of PTEN [58–60].

2.9. Angiogenesis. Angiogenesis is regulated by equilibrium between proangiogenic (i.e., VEGF, FGF, EGF, PDGF, HIF) and antiangiogenic factors (i.e., angioatin, IFN, thombospondin, and interleukins 1, 4, 12, 18, and 21) which are produced by both the malignant cells and the microenvironment including endothelial cells, fibroblasts, and immune cells. Vascular endothelial growth factor pathway plays a dominant role in the pathogenesis and biology of STS. VEGF is overexpressed in 25% of tumors, and high VEGF is associated with an increased risk of metastases and poorer prognosis. Strong VEGF expression is often present in tumors rich in vasculature and epithelioid features such as epithelioid sarcoma, KS, and ASPS. Serum VEGF levels have been strongly correlated with tumor grade and mass and usually poorly differentiated tumors. STS with high VEGF expression are associated with resistance to chemotherapy [61, 62]. As with IGF, the VEGF downstream pathway involves PI3K and MAPK indicative of intermingle of cell membrane signals. Distinct from these pathways is the VEGF-induced activation of PGLG1 which exerts proangiogenic effects via protein kinase C (PKC) [61].

Other proangiogenic factors are upregulated in STS including PDGFR, MMP-2, and Notch-1 and Notch-4, basic FGF and angiopoietin-2 with certain variability according to type and grade of the sarcoma. For instance, fibrosarcoma and LMS showed the highest bFGF levels [63]. Some chromosomal translocations and their fusion proteins can act as transcription factors for promoters of the VEGF gene as is the case of the highly vascular ASPS. Similarly the activation of mTOR may promote angiogenesis via control of the hypoxia inducible factor (HIF)-1α and mTOR inhibition results in an antiangiogenic effect [58].

2.10. Telomeres. Cell senescence has been considered a hallmark of cancer and has been related to chromosomal telomere maintenance mechanisms currently under scrutiny in several malignancies. In a LPS model, using high-resolution DNA mapping array, high level of genome instability and genetic amplifications were identified. In contrast to most stem cells and other cancer cells, that use reverse transcriptase telomerase for telomere maintenance, sarcoma cells activate the alternative lengthening of telomeres (ALT) mechanism as often as telomerase. ALT positive LPS have higher genetic instability and a worse prognosis than non-ALT tumors [64]. A genetic change, the deletion of chromosome 1q32.2-q44, is seemingly specific to the activation of ALT mechanism in this model [65].

2.11. Hedgehog (Hh) Pathway. Activation of Hh pathway results in stimulation of a wide range of prosurvival transcription factor genes. Abnormal activation of Hh pathway has been implicated in the genesis of various cancers particularly basal cell carcinoma, medulloblastomas, and RMS. Activation of Hh is manifested by the expression of several proteins (Ptc1, Gli1, Gli3, and Myf5). These markers are expressed by embryonal RMS and fusion gene-negative alveolar RMS, whereas FOXO1-PAX3/PAX7 positive ARMS are not [64]. Preliminary observations have shown augmented Hh signaling in cancer stem cells as well as in stromal nonmalignant cells surrounding malignant tumors and may constitute another cofactor in the genesis of sarcomas and other cancers [66].

2.12. Cancer Stem Cells and Mesenchymal Cells in Sarcoma. A growing body of evidence suggests the existence of cancer stem cells (CSCs), pluripotential stem cells that can perpetuate the generation or renewal of tumor forming cells in solid tumors [67]. The first evidence of cancer stem cells in sarcoma was reported in 2009. Using surgically resected ES primary tumors, a population of CD133 positive cells fulfilling in vitro and in vivo criteria of CSC was identified. These criteria included the capacity to generate and sustain tumor growth in a xenograft model and to differentiate, in vitro, along adiopogenic, osteogenic, and chondrogenic lineages [68]. These data are supportive of the mesenchymal stem cell (MSC) origin of ES. Thus, ES-initiating cells seem to conserve the properties of their putative cell precursors. In this model, the expression of the EWS-FLI-1 fusion protein in MSC cells was sufficient to develop ES-like tumors. Lastly, the CD133+ CSC studied showed significantly higher genetic instability and a worse prognosis than non-CD133+ tumors [64]. Preliminary observations have shown augmented Hh signaling in cancer stem cells as well as in stromal nonmalignant cells surrounding malignant tumors and may constitute another cofactor in the genesis of sarcomas and other cancers [66].

While testing other sarcoma-inducing fusion genes, only FUS-CHOP-expressing transfected cells were found to generate tumors resembling human myxoid LPS. Together with the findings in ES, these data raise the intriguing possibility that ES and MLS may originate from closely related mesenchymal cells, but at different anatomical locations. Perhaps the microenvironment (bone in ES, soft tissue in MLS) contributes to the line of differentiation that the MSC follow according to the adaptability of the transformed cell to survive in a given tissue environment [69].
2.13. Mesenchymal-Epithelial Transition in Sarcoma. Another puzzling and intriguing feature of certain sarcomas is the apparent spontaneous transition from a mesenchymal tumor to an epithelial enriched tumor (mesenchymal-epithelial transition (MET)). There is growing evidence supporting the role of epithelial-to-mesenchymal transition (EMT) during carcinoma progression and metastases linked to the consequences in cell morphology, cell-to-cell adhesion, cell motility, and plasticity to migrate and grow in the extracellular matrix. The mesenchymal to epithelial transition (MET) in sarcoma progression is considerably less well studied. Triggering of MET has been shown to be induced by c-met proto-oncogene, a TK receptor for HGF/SF. Increased expression of this protein leads to epithelial differentiation. Epigenetic regulation of DNA methylation has also been related to the MET [70].

This phenomenon is particularly notable in SS. Monophasic SS is entirely composed of spindle cells with or without solid epithelial areas, whereas the biphasic SS contains a lining of epithelial cells amongst the spindle cells [71]. At a molecular level, the SYT-SSX1 fusion occurs five times more frequently in biphasic SS exhibiting MET in comparison to SYT-SSX2 in monophasic SS. These data indicate a possible role of SYS-SSX1 and SYT-SSX2 in the MET phenomenon by interacting with transcription receptors (snail or slug, resp.) interfering with the E-cadherin gene and triggering the MET epithelial differentiation program in the affected SS cells [72].

Similar observations have been described in a chondrosarcoma model, where upregulation of 4 distinct epithelial markers and the downregulation of snail were found. Loss of DNA methylation was demonstrated in maspin and 14-3-σ genes leading to increased expression of these 2 epithelial-specific genes during chondrosarcoma genesis. These results support the relationship between MET and an epigenetic switch in chondrosarcoma [73].

2.14. MicroRNA in Sarcomas. The discovery of microRNA (miRNA) has been one further step into the molecular universe of gene regulation and cell biology and consequently into the biology of cancer cells and oncogenesis. There is an intense search for miRNA profiles in diverse human cancers to better understand the role of these minute RNA molecules in cancer control and to explore potential therapeutic implications [74].

Preliminary work in sarcomas has disclosed unique miRNA expression signatures according to the histological types seemingly reflecting the cell lineage and differentiation status of the tumors [75]. Hierarchical clustering of 87 miRNAs disclosed four main groups, whereby almost all SS, RMS, LMS, and GIST were grouped distinctively. In GIST, miR-221 and miR-222 had low expression, suggesting that the decreased suppressive activity of these miRNAs allows increased translation of KIT. The miRNAs that play a major role in myogenesis, miR-1, miR-133A, and miR-133B, were overrepresented in LMS, whereas miR-335, involved in skeletal muscle differentiation, was present in ARMS. In SS, miR-143 whose target is ERK5 (MAPK7), was expressed at very low levels suggesting that this miRNA may be involved in the expression of the SYT-SSX1 oncoprotein [76]. Others have linked the expression of miR-200 to mesenchymal-epithelial differentiation often reported in SS [77].

In a recent study exploring the genesis of CSC phenotype in ES, Riggi and collaborators [78] published evidence that repression of miRNA-145 and expression of the EWS-FLI-1 fusion gene were both necessary to induce transformation. They showed evidence that their common target may be the SOX2 gene. This gene is known to code for transcription factors required for the development of pluripotent stem cells. These observations provided valuable insight into the mechanisms, whereby a single oncogene (EWS-FLI1) can reprogram cells towards CSC.

3. Therapeutic Implications

Targeting the multiple molecular pathways and mechanisms summarized above is one of the areas of intense basic and clinical research. The objective is to find means to modify tumor behavior and to find long awaited clinical therapeutic options for these patients. Search for antagonistic antibodies, TK inhibitors, and inhibitors of downstream molecules of the PI3K, MAPK, and mTOR paths are at the forefront of these efforts (Figure 2). The preliminary clinical trials have not yet crystallized into therapeutic breakthroughs despite solid preclinical evidence, suggesting a broad range of favorable biological effects from the inhibition of these pathways.

3.1. IGF-1R Antibodies. Preclinical data proves that effective blockade of IGF-1 and IGFII ligands to the IGF-1R is feasible [79]. Monoclonal antibodies against the IGF-1R have been the favored approach to date. Phase I and II studies of IGFR1 antagonists figitumumab, cixutumumab, AMG479, R1507, and SCH 717454 either alone or in combination with other agents, are currently under clinical investigation for patients with sarcomas. Table 5 summarizes the results of reported phase I/II studies with anti-IGF-R1 agent [79–83].

Further, IGFR1 has been implicated in chemotherapy resistance from in vitro work with malignant cells. In an ES tumor model, combination of ADW742 with imatinib, vincristine, and doxorubicin induced a significant reduction of tumor cell growth, mainly by increasing apoptosis [84]. Similarly, NVP-AEW541 led to cytotoxicity and induced apoptosis in imatinib resistant or wildtype GIST [85]. Finally, there is experimental evidence that bidirectional crosstalk between the IGF system and the erbB family of receptors may confer means of escape or resistance to target therapy of these receptor pathways [51]. Thus, the use of combined therapies aiming to block several pathways simultaneously is being actively investigated in various tumors.

3.2. TKs Inhibitors and Antiangiogenesis. As described above, TKs account for a large number of defective signaling pathways in sarcomas. Based on the success of imatinib in GIST, TKs inhibitors are of major interest in other sarcomas. Sunitinib has been shown to be effective in imatinib-resistant...
Figure 2: Several ligands (IGF1/2, SCF, HGF, VEGF, and FGF) activate cell membrane receptor tyrosine kinases (IGF1R, C-KIT, C-MET, VEGFR-A, and FGFR) triggering shared interacting signal transduction pathways (PI3K/AKT, RAF/MAPK, and MTOR). The availability of ligands via paracrine secretion (IGF1), autocrine loops (VEGF), or ligand binding (IGFBPs) can modulate activation of these pathways. Molecular anomalies of the receptors or the downstream signals lead to constitutive activation or dysregulation of these signals. Multiple cell processes including proliferation, differentiation, angiogenesis, and survival are promoted as a result of the activation of these main pathways in sarcomas and other neoplasms. Actionable targets are listed that may interfere with the abnormal signalling and could result in beneficial biologic and clinical effects.

Table 5: Current Anti-IGF treatment of sarcomas.

| Monoclonal antibodies | Human trials | Disease control rate (CR, PR, and SD) | Comments |
|-----------------------|--------------|---------------------------------------|----------|
| Figitumab CP-751, 871 | ES/STS       | 10/28 (35%)                           | Anti-IGF-IR |
| Cixutumumab           | STS          | 22/37 (59%)                           | Liposarcomas; block hybrid receptors |
| Robatumumab SCH 717454| Preclinical  | OS, RMS                               | Anti-IGF-IR |
| Ganitumab AMG479      | ES           | 2/15 (13%)                            | No SD included |
| RI 507                | ES           | 18/125 (14.4%)                        |          |

| TK inhibitors Status | Target disease |
|----------------------|----------------|
| NVP-AEW541 Preclinical| ES/STS/GIST | Synergy with chemoRx |
| NVP-ADW 742 Preclinical| ES          | Synergy with imatinib |
| BMS-536924 Preclinical| STS         | ATP-competitive IGF-IR |

| Others Status | Target disease |
|---------------|----------------|
| Nordihydroguaiaretic acid (NDGA) Preclinical | STS | Disrupts IGF-1R; blocks HER-2 |

GISTs [86]. Patients with chordomas, desmoids, and DFSP tumors reportedly responded to imatinib in small trials and isolated case reports, likely via inhibition of PDGFR [87].

Initial attempts intended to block signaling pathways with other available agents known to interfere with either cellular receptors or TKs have not met with evidence of major or consistent clinical benefit. Phase II studies with EGFR inhibitors (gefitinib or erlotinib) showed no clinical activity in SS or malignant nerve-sheath tumors. Use of trastuzumab in ES and OS, alone or in combination with chemotherapy, has had no therapeutic benefit. Phase II studies with sunitinib in non-GIST sarcomas have only shown occasional objective responses, but disease stabilization over 12 weeks was noted in several histologies [87]. Sorafenib, but not sunitinib, was reported to produced a 14% PR rate and a median OS of 14.3 months in angiosarcomas [88]. Some
sarcoma subtypes with a predominant vascular connective tissue component such as angiosarcomas, intimal sarcomas, and hemangiopericytomas may arise from endothelial cells, suggesting that proangiogenic proteins may be relevant to their growth and potential treatment targets. Several multitargeted receptor TK inhibitors with antiangiogenic effects are currently on clinical trials. Table 6 shows published or reported data on various new multitargeted TKs [89–93].

**Table 6: Current clinical trials with tyrosine kinase inhibitors in sarcomas.**

| Agent         | Human trials | Clinical benefit rate (CR, PR, and SD) | Targets: notes |
|---------------|--------------|----------------------------------------|----------------|
| Imatinib      | GIST         | 85% (5% CR; 45% PR)                    | KIT. FDA Approved |
| Sunitinib     | GIST         | 65% (7% PR)                            | VEGFR-1, VEGFR-2, VEGFR-3, PDGFR α/β, KIT. FDA Approved |
| Sorafenib     | Angiosarcoma, GIST | 14%                                 | VEGFR-2, VEGFR-3, PDGFR, c-RAS, b-RAF, KIT |
| Pazopanib     | Palette STS  | PFS = 20 versus 7 weeks (P = 0.0001)   | VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α/β, KIT |
| Brivanib      | STS          | 30% overall                            | FGF and VEGF (FGF-positive did better) |
| Cediranib     | ASCO 2011    | 78% (43%, PR) Alveolar soft part sarcoma | VEGFR-1, VEGFR-2, and VEGFR-3 |
| Tivantinib    | ASCO 2011    | 80% (5%, PR) Clear cell sarcoma, ASPS  | c-Met |
| Axitinib      | STS, angiosarcoma | N/A                                | VEGFR-1, VEGFR-2, and VEGFR-3 |

**Table 7: Current clinical trials with rapalogs in sarcomas.**

| Agent         | Human trials | Clinical benefit rate (CR, PR, and SD) | Notes                        |
|---------------|--------------|----------------------------------------|------------------------------|
| Temsirolimus  | GIST         | GIST = 4/15 (27%)                      | Refractory GIST              |
| Temsirolimus  | ASCO 2010    | STS = 2/15 (13%)                      |                              |
| Temsirolimus  | Phase II STS | Mayo Clinic                            |                              |
| Sirolimus     | Kaposi sarcoma | 15/15 (100%)                      | Posttransplant KS             |
| Ridaforolimus | Phase II-STS | 61/212 (29%; 2% PR)                  | Dermal lesions                |
| Ridaforolimus | SUCEED trial | PFS: HR = 0.69 (P < 0.0001) (22.4 versus 14.7 weeks) | Maintenance after ChemoRX |

3.3. **mTOR Inhibitors.** The clinical impact of analogs of rapamycin (rapalogs) in the management of renal cell carcinoma has confirmed the antitumor potential of mTOR pathway interference [95]. The participation of mTOR in the genesis of sarcoma is related to the primordial role of the IGF system in these tumors. Thus, mTOR inhibitors were a natural choice to test clinically in sarcomas.

Rapamycin exert its biological effects by forming a complex with FKBP12 which binds to the FK-rapamycin binding domain of mTOR inhibiting the function of mTORC1-mediated signal pathway and resulting in a direct antiangiogenic effect [58]. A number of preclinical studies with various rapalogs paved the way to subsequent human trials. These have included *in vitro* and *in vivo* observations in mouse xenograft models using sirolimus, temsirolimus, everolimus, and ridaforolimus. Of relevance, temsirolimus inhibits HIF-1α translation and interferes with VEGF protein expression in RMS demonstrating suppressed tumor growth via anti-angiogenesis [96]. Other models have suggested that sarcomas associated with PTEN loss or inactivation may be particularly susceptible to the therapeutic effects of mTOR inhibitors [58, 59]. Rapalogs have been shown to be less effective or ineffective in the presence of KRas mutations or overexpression of Bcl2, whereas tumors with cyclin D1 expression and “angiogenesis addiction” are more susceptible [97].

Phase I/II clinical trials with several rapalogs and combinations aim to determine efficacy in sarcoma patients. Ongoing studies include testing efficacy of sirolimus in KS, temsirolimus, and valproic acid in OS and STS; or combinations with vinorelbine for uterine sarcoma, liposomal doxorubicin or irinotecan for recurrent or refractory sarcomas [96, 97]. Table 7 summarizes data on early phase studies with rapalogs. Ridaforolimus is a nonprodrug rapalog that has shown promising clinical activity in STS [98, 99]. Despite disputed clinical impact (the difference in median PFS was only 3 weeks), this drug is awaiting approval in 23 countries including the FDA in the US based on these studies.
3.4. Combinatorial Studies. A number of early clinical studies explored combination of agents intended to block redundant or cross-talking molecular pathways or to circumvent chemotherapy resistance. These include everolimus with imatinib, phase II study in imatinib-resistant GIST; everolimus and figitumumab; temsirolimus with cixutumumab in ES (65% of patients had tumor reduction >20%); ridaforolinimus and doxorubicin; everolimus and pegylated liposomal doxorubicin, mTOR inhibitors and hormonotherapy, and many others will follow [96–99]. There is also a growing interest in the use of other agents including melatonin, metformin, celecoxib, statins, and others which have been shown to modulate molecular signals in the pathways involved in tumor growth. Melatonin has been shown to have a broad range of activities resulting in an oncostatic effect in vitro and in vivo including suppression of tumorigenesis in methylcholanthrene-induced fibrosarcomas in mice [100]. In an ES in vitro model, melatonin has been shown to induce apoptosis and synergism when combined with chemotherapeutic agents [101]. Metformin reduces insulin level by decreasing insulin resistance a favorable effect on cancer cells dependent on the IGF system. A direct inhibitory effect of metformin on cancer cell growth has also been reported and has been associated to a regulatory role in the AMP-activated protein kinase (AMPK) and mTOR pathways [102].

4. Conclusions

A wealth of information is accumulating at a rapid pace that, undoubtedly, will continue to contribute to the further understanding of the molecular biology of sarcomas. There are, however, enormous challenges ahead, particularly in the clinical translation of these discoveries. Despite the success noted in KS and the success of imatinib treatment in GIST, only modest gains have been attained in our attempts to alter or modulate growth of tumor in most other sarcomas. It is clear that the rarity of this vast number of pathological entities complicates the clinical application of the newly developing agents. But the existence of fairly specific genetic abnormalities, mainly specific translocations and a generation of discernible fusion genes in various sarcomas make research in these tumors an attractive mold for advancing studies of solid tumors.

Finding key molecular “nodes” or pathways that are common amongst these tumors will help to further understand the pathogenesis of sarcomas and may help improve current therapeutic choices. Yet, the redundancy of these molecular cascades, the loopholes and the fact that tumors may find adaptive escape routes necessitate incessant search for deeper understanding of the signaling pathways in the context of all the hallmarks of cancer discussed above. The concept of system biology and the development of computational and mathematical models are areas that will facilitate the organization of thoughts directing future research strategies.

Clinically, biologic effects are largely cytostatic and transient which indicate the need to devise new strategies to reach long-term clinical control and potential cure of some of these entities. Newer clinical trials are beginning to modify the chemotherapy-oriented criteria of response and criteria in the designing of clinical studies [103]. Emphasis is being placed in the selection of patient populations to avoid the pitfalls of unselected trials that have often missed the target in the past. There is a clear trend to consider progression-free survival (PFS) as a more relevant endpoint when assessing the antitumor effects of molecular targeted therapies. It has been suggested that first-line treatments should achieve PFS rates of >30% at 6 months for the results to be considered clinically meaningful in phase II trials in STS [86].

Assessment of “metabolic” response by FDG-PET is being examined as a better mean of assessing antitumor activity of targeted therapies as opposed to traditional RECIST-defined responses. Support for this is coming in many fields including sarcoma trials [104]. FDG-PET has been shown superior to CT in predicting early response and monitoring of response and progression to imatinib therapy in GIST and other STS [105, 106]. Furthermore, FDG-PET may also have applicability as an early pharmacodynamic marker of molecular targeted therapies [106].

Although the concept of “personalized” therapy has been overestimated there is clearly a need to continue searching for uniqueness among subgroups of patients, particularly in sarcomas, this most heterogeneous collection of diseases. Cardinal to these efforts is the search for molecular markers that identify patients most likely to benefit from a given intervention as well as to monitor the biological effects of the treatment or to identify the optimal dose of these agents. It is necessary to dismiss the chemotherapy-driven concept of maximum tolerated dose and find instead the optimal biologic dose of the agents being tested. So far the identification of clinically relevant molecular markers has been daunting but progress in the area is expected as methodologies to examine efficiently multitude putative “markers of interest” are developed.

These interventions are not strictly tumor-specific and elicit cellular and clinical toxicity and may hamper our enthusiasm to some extent as we have already witnessed in other fields including RCC, melanoma, colon, breast, and other cancers. The identification of more precise targets and refinement of the specificity of targeted agents is required to make progress in this field. These targets should be those that are essential for the malignant cells to subsist, a concept that has been termed “oncogene addiction.” But even well-characterized mutations can have different molecular isoforms that could alter the specificity and durability of the binding to the therapeutic agent or render the agent less efficacious. Identification of precise “pockets” within the abnormal targeted molecule may also improve the therapeutic index of future targeted therapies.

Enormous clinical challenges lie ahead, but a new world of possibilities is opening. Combination strategies are very attractive because of the multitude of potential targets and because of the different properties and mechanisms of action of drugs in our growing arsenal. However, the combination of some of these agents has already shown additive toxicities without an additional antitumor effect. Antagonism has been observed in some combinations that seemed logical and
promising and, although observed in preclinical models, we are yet to prove synergism when combining these agents. Combination therapies should not be limited to molecular-targeted drugs as we can judiciously combine these with chemotherapeutic agents. Furthermore, these combination strategies must include efforts to modulate the microenvironment of the tumor and the immune system to attain a full and comprehensive approach to the control of the malignant growth in sarcomas and other cancers.

Acknowledgments

The authors wish to express their gratitude to Dr. Robert Brown for reviewing the paper and Ms. Marika Stepankiw for her editorial input.

References

[1] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
[2] P. Rous, “A sarcoma of the fowl transmissible by an agent separable from the tumor cells,” The Journal of Experimental Medicine, vol. 13, pp. 397–411, 1911.
[3] H. Rubin, “The early history of tumor virology: Rous, RIP, and RAV,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 35, pp. 14389–14396, 2011.
[4] J. S. Butel, “Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease,” Carcinogenesis, vol. 21, no. 3, pp. 405–426, 2000.
[5] R. J. Huebner and G. J. Todaro, “Oncogenes of rna tumor viruses as determinants of cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 64, no. 3, pp. 1087–1094, 1969.
[6] D. Stehelin, H. E. Varmus, J. M. Bishop, and P. K. Vogt, “DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA,” Nature, vol. 260, no. 5547, pp. 170–173, 1976.
[7] E. R. Fearon and B. Vogelstein, “A genetic model for colorectal tumorigenesis,” Cell, vol. 61, no. 5, pp. 759–767, 1990.
[8] M. Malumbres and M. Barbacid, “RAS oncogenes: the first 30 years,” Nature Reviews Cancer, vol. 3, no. 6, pp. 459–465, 2003.
[9] D. S. Goodsell, “The molecular perspective: the RAS oncogene,” Oncologist, vol. 4, no. 3, pp. 263–264, 1999.
[10] J. Downward, “Targeting ras signalling pathways in cancer therapy,” Nature Reviews Cancer, vol. 3, no. 1, pp. 11–22, 2003.
[11] J. Bickels, Y. Kollender, O. Merinsky, and I. Meller, “Coley’s toxin: historical perspective,” Israel Medical Association Journal, vol. 4, no. 6, pp. 471–472, 2002.
[12] I. Gresser, “Antitumor effects of interferon,” Advances in Cancer Research, vol. 16, pp. 97–140, 1973.
[13] H. Strander, “Interferons and osteosarcoma,” Cytokine and Growth Factor Reviews, vol. 18, no. 5–6, pp. 373–380, 2007.
[14] L. C. Platanias, “Mechanisms of type-I- and type-II-interferon-mediated signalling,” Nature Reviews Immunology, vol. 5, no. 5, pp. 375–386, 2005.
[15] T. Panaretakis, L. Hjortsberg, K. P. Tamm, A. C. Björklund, B. Joseph, and D. Grander, “Interferon α induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin,” Molecular Biology of the Cell, vol. 19, no. 1, pp. 41–50, 2008.
[16] M. S. R. Hutt, “Historical introduction, burkitt’s lymphoma, nasopharyngeal carcinoma and Kaposi’s sarcoma,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 75, no. 6, pp. 761–765, 1981.
[17] V. Beral, T. A. Peterman, R. L. Berkelman, and H. W. Jaffe, “Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection?” The Lancet, vol. 335, no. 8682, pp. 123–128, 1990.
[18] P. S. Moore and Y. Chang, “Detection of herpesvirus-like dna sequences in Kaposi’s sarcoma in patients with and those without HIV infection,” New England Journal of Medicine, vol. 332, no. 18, pp. 1181–1185, 1995.
[19] J. T. West and C. Wood, “The role of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression,” Oncogene, vol. 22, no. 33, pp. 5150–5163, 2003.
[20] R. G. Jenner, K. Maillard, N. Cattini et al., “Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10399–10404, 2003.
[21] H. W. Wang, M. W. B. Trotter, D. Lagos et al., “Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lyphoditic endothelial gene expression in Kaposi sarcoma,” Nature Genetics, vol. 36, no. 7, pp. 687–693, 2004.
[22] S. E. Krown, F. X. Real, and S. Cunningham Rundles, “Preliminary observations on the effect of recombinant leukocyte a interferon in homosexual men with Kaposi’s sarcoma,” New England Journal of Medicine, vol. 308, no. 18, pp. 1071–1076, 1983.
[23] A. Rios, P. W. A. Mansell, G. R. Newell et al., “Treatment of acquired immunodeficiency syndrome-related Kaposi’s sarcoma with lymphoblastoid interferon,” Journal of Clinical Oncology, vol. 3, no. 4, pp. 506–512, 1985.
[24] P. Besmer, W. D. Hardy Jr., E. E. Zuckerman et al., “The hardy-zuckerman 2-FeSV, a new feline retrovirus with oncogene homology to abelson-MuLV,” Nature, vol. 303, no. 5920, pp. 825–828, 1983.
[25] Y. Yarden, W. I. Kuang, T. Yang-Feng et al., “Human proto-oncogene c-KIT: a new cell surface receptor tyrosine kinase for an unidentified ligand,” EMBO Journal, vol. 6, no. 11, pp. 3341–3351, 1987.
[26] K. Sircar, B. R. Hewlett, J. D. Huizinga, K. Chorneyko, I. Berezin, and R. H. Riddell, “Interstitial cells of cajal as precursors of gastrointestinal stromal tumors,” American Journal of Surgical Pathology, vol. 23, no. 4, pp. 377–389, 1999.
[27] S. Hirota, K. Isozaki, Y. Moriyama et al., “Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors,” Science, vol. 279, no. 5350, pp. 577–580, 1998.
[28] M. C. Heinrich, B. P. Rubin, B. J. Longley, and J. A. Fletcher, “Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations,” Human Pathology, vol. 33, no. 5, pp. 484–495, 2002.
[29] P. Reichardt, ”Optimal use of targeted agents for advanced gastrointestinal stromal tumours,” Oncology, vol. 78, no. 2, pp. 130–140, 2010.
[30] M. C. Heinrich, D. J. Griffith, B. J. Druker, C. L. Wait, K. A. Ott, and A. J. Zigler, “Inhibition of c-KIT receptor tyrosine kinase activity by STI 571 a selective tyrosine kinase inhibitor,” Blood, vol. 96, no. 3, pp. 925–932, 2000.
[31] D. A. Tuveson, N. A. Willis, T. Jacks et al., “STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications,” Oncogene, vol. 20, no. 36, pp. 3054–3058, 2001.
[32] H. Joensuu, P. J. Roberts, M. Sarlomo-Rikala et al., ”Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor,” New England Journal of Medicine, vol. 344, no. 14, pp. 1052–1056, 2001.
[33] G. D. Demetri, M. Von Mehren, C. D. Blanke et al., “Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors,” New England Journal of Medicine, vol. 347, no. 7, pp. 472–480, 2002.
[34] S. Singer, B. P. Rubin, M. L. Lux et al., ”Prognostic value of kit mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors,” Journal of Clinical Oncology, vol. 20, no. 18, pp. 3898–3905, 2002.
[35] S. Bauer, A. Duensing, G. D. Demetri, and J. A. Fletcher, ”KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: P13-kinase/AKT is a crucial survival pathway,” Oncogene, vol. 26, no. 54, pp. 7560–7568, 2007.
[36] E. Álava, ”Molecular pathology in sarcomas,” Clinical and Translational Oncology, vol. 9, no. 3, pp. 130–144, 2007.
[37] J. V. M. G. Bovée and P. C. W. Hogendoorn, ”Molecular pathology of sarcomas: concepts and clinical implications,” Virchows Archiv, vol. 456, no. 2, pp. 193–199, 2010.
[38] Y. Oda and M. Tsuneyoshi, ”Recent advances in the molecular pathology of soft tissue sarcoma: implications for diagnosis, patient prognosis, and molecular target therapy in the future,” Cancer Science, vol. 100, no. 2, pp. 200–208, 2009.
[39] L. J. Helman and P. Meltzer, ”Mechanisms of sarcoma development,” Nature Reviews Cancer, vol. 3, no. 9, pp. 685–694, 2003.
[40] F. Mertens, I. Panagopoulos, and N. Mandahl, ”Genomic characteristics of soft tissue sarcomas,” Virchows Archiv, vol. 456, no. 2, pp. 129–139, 2010.
[41] M. C. Le Deley, O. Delattre, K. L. Schaefer et al., ”Impact of EWS-ETS fusion type on disease progression in ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial,” Journal of Clinical Oncology, vol. 22, no. 20, pp. 4040–4050, 2004.
[42] O. Delattre, J. Zucman, B. Plougastel et al., ”Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours,” Nature, vol. 359, no. 6391, pp. 162–165, 1992.
[43] F. G. Barr, ”Translocations, cancer and the puzzle of specificity,” Nature Genetics, vol. 19, no. 2, pp. 121–124, 1998.
[44] S. R. Knezevich, D. E. McFadden, W. Tao, J. F. Lim, and P. H. B. Sorensen, ”A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma,” Nature Genetics, vol. 18, no. 2, pp. 184–187, 1998.
[62] R. I. Olsen, S. R. Taratunolo, and S. H. Hinrichs, “Molecular approaches to sarcoma therapy,” *Sarcoma*, vol. 6, no. 1, pp. 27–42, 2002.

[63] S. S. Yoon, N. H. Segal, P. J. Park et al., “Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression,” *Journal of Surgical Research*, vol. 155, no. 2, pp. 282–290, 2006.

[64] A. Costa, M. G. Daidone, L. Daprai et al., “Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression,” *Cancer Research*, vol. 66, no. 17, pp. 8918–8924, 2006.

[65] J. E. Johnson, E. J. Gettings, J. Schwalin et al., “Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms,” *Cancer Research*, vol. 67, no. 19, pp. 9221–9228, 2007.

[66] N. Takebe, P. J. Harris, R. Q. Warren, and S. P. Ivy, “Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways,” *Nature Reviews Clinical Oncology*, vol. 8, no. 2, pp. 97–106, 2011.

[67] C. T. Jordan, “Cancer stem cell biology: from leukemia to solid tumors,” *Current Opinion in Cell Biology*, vol. 16, no. 6, pp. 708–712, 2004.

[68] M. L. Suvà, N. Riggi, J. C. Stehle et al., “Identification of cancer stem cells in ewing’s sarcoma,” *Cancer Research*, vol. 69, no. 5, pp. 1776–1781, 2009.

[69] N. Riggi, L. Cironi, P. Provero et al., “Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma,” *Cancer Research*, vol. 66, no. 14, pp. 7016–7023, 2006.

[70] C. L. Chaffer, E. W. Thompson, and E. D. Williams, “Mesenchymal to epithelial transition in development and disease,” *Cells Tissues Organs*, vol. 185, no. 1–3, pp. 7–19, 2007.

[71] W. B. Laskin and M. Miettinen, “Epithelial-type and neural-type cadherin expression in malignant noncarcinomatous neoplasms with epithelialoid features that involve the soft tissues,” *Archives of Pathology and Laboratory Medicine*, vol. 126, no. 4, pp. 425–431, 2002.

[72] T. Saito, M. Nagai, and M. Ladanyi, “SYT-SSX and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma,” *Cancer Research*, vol. 66, no. 14, pp. 6919–6927, 2006.

[73] M. P. Fitzgerald, F. Gourronc, M. L. T. Teoh et al., “Human chondrosarcoma cells acquire an epithelial-like gene expression pattern via an epigenetic switch: evidence for mesenchymal-epithelial transition during sarcomagenesis,” *Sarcoma*, vol. 2011, Article ID 598218, 11 pages, 2011.

[74] P. Gammell, “Micromas: recently discovered key regulators of proliferation and apoptosis in animal cells: identification of mirnas regulating growth and survival,” *Cytotechnology*, vol. 53, no. 1–3, pp. 55–63, 2007.

[75] S. Subramanian, W. O. Lui, C. H. Lee et al., “Microrna expression signature of human sarcomas,” *Oncogene*, vol. 27, no. 14, pp. 2015–2026, 2008.

[76] M. Hisaoka, A. Matsuyama, Y. Nagao et al., “Identification of altered microrna expression patterns in synovial sarcoma,” *Genes Chromosomes and Cancer*, vol. 50, no. 3, pp. 137–145, 2011.

[77] T. Mioi, A. Kumagai, A. Yoshida et al., “MicroRNA-200a Expression in Synovial Sarcoma Is Related to Epithelial Differentiation,” *Abstract 65*, http://www.abstracts2view.com/uscap11/.

[78] N. Riggi, M. L. Suvà, C. De Vito et al., “EWS-FLI-1 modulates mirRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward ewing sarcoma cancer stem cells,” *Genes and Development*, vol. 24, no. 9, pp. 916–932, 2010.

[79] S. J. Weroha and P. Haluska, “GF-1 receptor inhibitors in clinical trials—early lessons,” *Journal of Mammary Gland Biology and Neoplasia*, vol. 13, no. 4, pp. 471–483, 2008.

[80] D. Olimos, S. Postel-Vinay, L. R. Molife et al., “Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R -1R antibody figitumumab (CP-751,871) in patients with sarcoma and ewing’s sarcoma: a phase I expansion cohort study,” *The Lancet Oncology*, vol. 11, no. 2, pp. 129–135, 2010.

[81] P. J. Houghton, C. L. Morton, R. Gorlick et al., “Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program,” *Pediatric Blood and Cancer*, vol. 54, no. 7, pp. 921–926, 2010.

[82] A. W. Tolcher, J. Sarantopoulos, A. Patnaik et al., “Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1,” *Clinical Journal of Oncology*, vol. 27, no. 34, pp. 5800–5807, 2009.

[83] A. S. Pappo, S. Patel, J. Crowley et al., “Activity of R1507, a monoclonal antibody to the insulinlike growth factor-1 receptor (IGF1R), in patients with recurrent or refractory Ewing’s sarcoma family of tumors (ESFT): results of a phase II SARC study,” *Clinical Journal of Oncology*, vol. 28, supplement 15, abstract 10000, 2010.

[84] A. S. Martins, C. Mackintosh, D. Herrero Martin et al., “Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in ewing tumor,” *Cancer Research*, vol. 12, no. 11, pp. 3532–3540, 2006.

[85] A. K. Godwin, L. Rink, T. Chi et al., “Insulin-like growth factor 1 receptor (IGF-1R): a potential therapeutic target for gastrointestinal stromal tumors (GIST),” *Journal of Clinical Oncology*, vol. 26, supplement, abstract 10507, 2008.

[86] S. George, P. Merriam, R. G. Maki et al., “Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas,” *Journal of Clinical Oncology*, vol. 27, no. 19, pp. 3154–3160, 2009.

[87] B. Homet Moreno, E. Garralda Cabanas, and R. Hitt, “Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas,” *Clinical and Translational Oncology*, vol. 12, no. 7, pp. 468–472, 2010.

[88] R. G. Maki, D. R. D’Adamo, M. L. Keohan et al., “Phase II study of sorafenib in patients with metastatic or recurrent sarcomas,” *Clinical Journal of Oncology*, vol. 27, no. 19, pp. 3133–3140, 2009.

[89] S. Siejfer, I. Ray-Coquard, Z. Papai et al., “Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma,” *Clinical Cancer Research*, vol. 12, no. 7, pp. 1893–1900, 2006.

[90] W. T. Van Der Graaf, J. Blay, and S. P. Chawla, “PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy,” *Journal of Clinical Oncology*, vol. 29, supplement, abstract LBA10002, 2011.
[91] G. S. Schwartz, R. G. Maki, M. J. Ratain et al., “Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): biomarker and subset results of a phase II randomized discontinuation trial,” *Journal of Clinical Oncology*, vol. 29, supplement, abstract 10000, 2011.

[92] S. Kummar, A. Strassberger, A. Monks et al., “An evaluation of cediranib as a new agent for alveolar soft part sarcoma,” *Journal of Clinical Oncology*, vol. 29, supplement, abstract 10001, 2011.

[93] J. Goldberg, G. D. Demetri, E. Choy et al., “Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors,” *Journal of Clinical Oncology*, vol. 27, supplement 15, abstract 10502, 2009.

[94] R. F. Riedel, “Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches,” *Cancer*, vol. 118, no. 6, pp. 1474–1485, 2012.

[95] R. J. Amato and J. Jac, “Targeted anti-cancer therapies for renal cancer,” *Drugs*, vol. 66, no. 17, pp. 2161–2171, 2006.

[96] V. M. Rivera, R. M. Squillace, D. Miller et al., “Ridaforolimus (AP23573; MK-8669), a potent mtor inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens,” *Molecular Cancer Therapeutics*, vol. 10, no. 6, pp. 1059–1071, 2011.

[97] M. Agulnik, “New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma,” *Cancer*, vol. 118, no. 6, pp. 1486–1497, 2012.

[98] S. P. Chawla, J. Blay, I. L. Ray-Coquard et al., “Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy,” *Journal of Clinical Oncology*, vol. 29, supplement, abstract 10005, 2011.

[99] S. Vemulapalli, A. Mita, Y. Alvarado, K. Sankhala, and M. Mita, “The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas,” *Targeted Oncology*, vol. 6, no. 1, pp. 29–39, 2011.

[100] C. R. Vijayalaxmi, R. Thomas, R. Reiter, and T. S. Herman, “Melatonin: from basic research to cancer treatment clinics,” *Journal of Clinical Oncology*, vol. 20, no. 10, pp. 2575–2601, 2002.

[101] S. Casado-Zapico, J. Rodriguez-Blanco, G. García-Santos et al., “Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway,” *Journal of Pineal Research*, vol. 48, no. 1, pp. 72–80, 2010.

[102] I. B. Sahra, Y. L. Marchand-Brustel, J. F. Tanti, and F. Bost, “Metformin in cancer therapy: a new perspective for an old antidiabetic drug?” *Molecular Cancer Therapeutics*, vol. 9, no. 5, pp. 1092–1099, 2010.

[103] S. Richter, D. Pink, P. Hohenberger et al., “Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST,” *Journal of Clinical Oncology*, vol. 28, 15s, supplement, abstract 10038, 2010.

[104] C. C. Jaffe, “Response assessment in clinical trials: implications for sarcoma clinical trial design,” *Oncologist*, vol. 13, supplement 2, pp. 14–18, 2008.

[105] I. Gayed, T. Vu, R. Iyer et al., “The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors,” *Journal of Nuclear Medicine*, vol. 45, no. 1, pp. 17–21, 2004.